If you've ever been in a hospital, you've seen them — those unassuming devices on IV poles, quietly delivering precise doses of medication. Infusion pumps don't get a lot of attention, but they're among the most critical devices in healthcare.
And the market is growing fast. Valued at $9 billion in 2024, the global infusion pumps and devices market is projected to reach $14.2 billion by 2030 — a 7.9% CAGR.
The growth story has several dimensions.
The chronic disease burden keeps expanding. Diabetes, cancer, cardiovascular disease, autoimmune conditions — they all rely on infusion-based drug delivery, and their prevalence is rising globally.
Healthcare is moving out of the hospital. The surging demand for ambulatory infusion pumps reflects a broader shift toward outpatient and home-based care. Patients want treatment continuity without extended hospital stays, and portable, user-friendly pump technology makes that possible.
The technology is getting smarter. Smart infusion pumps with dose error reduction systems, wireless EHR connectivity and automated medication management are becoming standard — reducing medication errors while improving clinical workflow efficiency.
And demographics are working in the market's favor. The growing elderly population requires disproportionately more infusion-based treatments.
North America leads with 42.5% market share. Key players include Baxter, B. Braun, BD, Medtronic, ICU Medical, Insulet and Tandem Diabetes Care.
**Curious about the competitive landscape?** Download the free overview of our report *Infusion Pumps and Devices: Technologies and Global Markets* for detailed product segmentation, technology assessment and regional analysis.
[Download the Free Report Overview →]
